Table 1.

Demographic and clinical features in VPSV and VPSWOV patients

No	Age/ gender	Risk factors	Time from diagnosis to shunt (m)	neurological deficit		antifungal therapy	Outcome 1 m
				Before VPS	After VPS improved
				VPSV
1	38/M	Hepatitis B	4	H,VL,HL	H	AMBisome+Fluc+5FC	better
2	36/M	Hepatitis B, Liver cirrhosis	1.5	H,VL,LOC	H,VL,LOC	AMB + Fluc+5FC	worse
3	40/M	Diabetes mellitus	3	H/V	H	AMB + Fluc+5FC	better
4	17/M		3.5	H/V,VL,LOC	H/V,VL,LOC	AMB + Fluc+5FC	better
5	28/M		1.5	H/V,VL	H,VL	Fluc+5FC	better
6	53/M		6	V, LOC	V, LOC	AMB + Fluc+5FC	better
7	27/M	pulmonary cryptococcosis	3	H/V,VL	H/V	AMB + Fluc+5FC	better
8	21/M		5	H	H	AMB + Fluc+5FC	better
9	31/M	Hepatitis B, Diabetes mellitus	6	H,VL	H,VL	Fluc+5FC	better
10	19/M	AIHA	4	H/V,CO	H/V,CO	AMB + Fluc+5FC	better
11	18/M	Hepatitis B	2	H/V	H/V	AMB + Fluc+5FC	better
12	53/F		3.5	V,LOC	V,LOC	AMB + Fluc+5FC	better
13	50/M	Hepatitis B	6	H,VL	H	Fluc+5FC	better
				VPSWOV
14	41/F	pulmonary cryptococcosis	4	H/V	H	AMB + Fluc+5FC	better
15	35/M		3	H/V,VL,LOC	H/V,VL,LOC	AMB + Fluc+5FC	better
16	40/M	pulmonary cryptococcosis	3	H/V,VL,HL	H/V,VL	AMB + Fluc+5FC	better
17	51/M	Diabetes mellitus	0.5	H/V,VL	H/V,VL	AMB + Fluc+5FC	better
18	41/M		2	H,VL, CO	H,VL	AMB + Fluc+5FC	better
19	61/F	Malignancy	4	H/V	H/V	Fluc+5FC	worse
20	37/M	Hepatitis B	2	H/V,VL,HL	H/V,VL	AMB + Fluc+5FC	better
21	55/F	SLE	0.5	H/V,VL	H/V,VL	Fluc+5FC	better
22	17/M	pulmonary cryptococcosis	1	H/V,LOC	H/V,LOC	AMB + Fluc+5FC	better
23	45/F	AIHA	1	H,VL,HL,LOC	H,VL	AMB + Fluc+5FC	NA

AIHA autoimmune haemolytic anaemia, SLE systemic lupus erythematosus, H/V headache and vomiting, VL visual loss, HL hearing loss, LOC loss of consciousness, CO convulsions, NA Not available, AMB Amphotericin B, 5FC flucytosine, Fluc Fluconazole, M month, 1–13: VPSV, 14–23: VPSWOV